OBJECTIVE: To assess the respective value of phenotype versus genotype versus standard of care for choosing antiretroviral therapy in patients failing protease inhibitor-containing regimens. METHODS:Patients with plasma HIV-1 RNA exceeding 1000 copies/ml were randomly allocated to phenotyping, genotyping, or standard of care. RESULTS:Five-hundred and forty-one patients were randomized, 190 to phenotyping, 192 to genotyping and 159 to standard of care. The baseline median CD4 cell count (280 x 106 cells/l), the plasma HIV-1 RNA level (4.3 log10 copies/ml), and the number of drugs previously received (n = 6) were similar in the three arms. More patients in the standard-of-care arm received at least three new drugs (55% versus 20% in the other arms; P < 0.001) and a regimen containing drugs from the three different classes. Plasma HIV-1 RNA was < 200 copies/ml at week 12 in 35% of patients in the phenotyping arm, 44% in the genotyping arm and 36% in the standard-of-care arm (phenotyping versus standard of care, P = 0.918; genotyping versus standard of care, P = 0.120). In a secondary analysis of 179 patients experiencing a first protease inhibitor failure, the percentage of patients achieving HIV-1 RNA <; 200 copies/ml was significantly higher in the genotyping arm (65%) than in the phenotyping (45%) and the standard-of-care arms (45%) (genotyping versus standard of care, P = 0.022). CONCLUSIONS: Overall, resistance assays did not demonstrate benefit over standard of care. In patients with the most limited protease inhibitor experience, a significant benefit was observed in the genotyping arm.
RCT Entities:
OBJECTIVE: To assess the respective value of phenotype versus genotype versus standard of care for choosing antiretroviral therapy in patients failing protease inhibitor-containing regimens. METHODS:Patients with plasma HIV-1 RNA exceeding 1000 copies/ml were randomly allocated to phenotyping, genotyping, or standard of care. RESULTS: Five-hundred and forty-one patients were randomized, 190 to phenotyping, 192 to genotyping and 159 to standard of care. The baseline median CD4 cell count (280 x 106 cells/l), the plasma HIV-1 RNA level (4.3 log10 copies/ml), and the number of drugs previously received (n = 6) were similar in the three arms. More patients in the standard-of-care arm received at least three new drugs (55% versus 20% in the other arms; P < 0.001) and a regimen containing drugs from the three different classes. Plasma HIV-1 RNA was < 200 copies/ml at week 12 in 35% of patients in the phenotyping arm, 44% in the genotyping arm and 36% in the standard-of-care arm (phenotyping versus standard of care, P = 0.918; genotyping versus standard of care, P = 0.120). In a secondary analysis of 179 patients experiencing a first protease inhibitor failure, the percentage of patients achieving HIV-1 RNA < 200 copies/ml was significantly higher in the genotyping arm (65%) than in the phenotyping (45%) and the standard-of-care arms (45%) (genotyping versus standard of care, P = 0.022). CONCLUSIONS: Overall, resistance assays did not demonstrate benefit over standard of care. In patients with the most limited protease inhibitor experience, a significant benefit was observed in the genotyping arm.
Authors: Jaideep Ravela; Bradley J Betts; Francoise Brun-Vézinet; Anne-Mieke Vandamme; Diane Descamps; Kristel van Laethem; Kate Smith; Jonathan M Schapiro; Dean L Winslow; Caroline Reid; Robert W Shafer Journal: J Acquir Immune Defic Syndr Date: 2003-05-01 Impact factor: 3.731
Authors: H H Hirsch; H Drechsler; A Holbro; F Hamy; P Sendi; K Petrovic; T Klimkait; M Battegay Journal: Eur J Clin Microbiol Infect Dis Date: 2005-11 Impact factor: 3.267
Authors: Robert W Shafer; Soo-Yon Rhee; Deenan Pillay; Veronica Miller; Paul Sandstrom; Jonathan M Schapiro; Daniel R Kuritzkes; Diane Bennett Journal: AIDS Date: 2007-01-11 Impact factor: 4.177
Authors: Joke Snoeck; Rami Kantor; Robert W Shafer; Kristel Van Laethem; Koen Deforche; Ana Patricia Carvalho; Brian Wynhoven; Marcelo A Soares; Patricia Cane; John Clarke; Candice Pillay; Sunee Sirivichayakul; Koya Ariyoshi; Africa Holguin; Hagit Rudich; Rosangela Rodrigues; Maria Belen Bouzas; Françoise Brun-Vézinet; Caroline Reid; Pedro Cahn; Luis Fernando Brigido; Zehava Grossman; Vincent Soriano; Wataru Sugiura; Praphan Phanuphak; Lynn Morris; Jonathan Weber; Deenan Pillay; Amilcar Tanuri; Richard P Harrigan; Ricardo Camacho; Jonathan M Schapiro; David Katzenstein; Anne-Mieke Vandamme Journal: Antimicrob Agents Chemother Date: 2006-02 Impact factor: 5.191
Authors: Y Yazdanpanah; M Vray; J Meynard; E Losina; M C Weinstein; L Morand-Joubert; S J Goldie; H E Hsu; R P Walensky; C Dalban; P E Sax; P M Girard; K A Freedberg Journal: HIV Med Date: 2007-10 Impact factor: 3.180